If these data can be confirmed beyond breast cancer models in mice, the utility of targeting CCR2 may well extend beyond its effects on immunosuppressive cells in the tumor microenvironment to encompass direct effects on tumor cells themselves. Here, CCR2 is linked to neoplasm.